ProQR shareholders approve 2026 AGM resolutions
ProQR Therapeutics N.V. reports the results of its 2026 annual general meeting held on June 2, 2026.
Rhea-AI Filing Summary
ProQR Therapeutics N.V. reports the results of its 2026 annual general meeting held on June 2, 2026. Shareholders adopted the 2025 annual accounts and appropriation of net result with 99.7% of votes cast in favor.
They granted discharge from liability to Board members for their 2025 duties with 69.5% support and approved the appointment of Dr. Lykke Hinsch Gylvin as a non-executive Board member with 99.7% support. KPMG Accountants N.V. was appointed external auditor for the 2027 financial year with 99.8% approval.
Shareholders also approved amendments to the Articles of Association to increase authorized capital with 65.4% support, authorized the Board to issue ordinary shares with 64.3% support, and to repurchase ordinary shares with 66.7% support. Following the meeting, the Board confirmed updated Audit, Compensation/Nominating/Corporate Governance, and Research and Development committee compositions.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
Articles of Association regulatory
authorized capital financial
non-executive member of the Board financial
external auditor financial
Audit Committee financial
Compensation, Nominating and Corporate Governance Committee financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who was appointed as ProQR’s new non-executive Board member in 2026?
Which audit firm will serve as ProQR’s external auditor for the 2027 financial year?
How did ProQR structure its Board committees after the June 2, 2026 AGM?
AI-generated analysis. How Rhea-AI works. Not financial advice.